The US choledocholithiasis market is supported by the high prevalence of gallstone disease, advanced diagnostic capabilities, and widespread adoption of minimally invasive procedures such as endoscopic retrograde cholangiopancreatography (ERCP). Strong healthcare infrastructure, increasing awareness of early diagnosis, and continuous advancements in gastrointestinal care are driving market...